SEC Form 4 · Updated Daily
LGND
— LIGAND PHARMACEUTICALS INCORPORATED OwnershipInsider and institutional ownership derived from SEC Form 4 filings. Click any owner to see their holdings across every company they’ve filed on, and how their position has changed over time.
Current Reporting Owners
| Owner | Role | Shares Owned | As Of | Last Activity |
|---|---|---|---|---|
| Loeb Daniel S | Director | 2,027,378 | 2007-03-26 | S |
| INVESTMENT 10 LLC | Reporting Owner | 1,855,083 | 2014-02-18 | S |
| GOLDMAN SACHS & CO | 10%+ Owner | 686,330 | 2020-02-03 | — |
| GOLDMAN SACHS GROUP INC/ | 10%+ Owner | 686,330 | 2020-02-03 | — |
| HIGGINS JOHN L | Director | 417,695 | 2022-12-28 | F |
| BVF PARTNERS L P/IL | 10%+ Owner | 248,144 | 2014-03-24 | S |
| BIOTECHNOLOGY VALUE FUND L P | 10%+ Owner | 248,144 | 2014-03-24 | S |
| BIOTECHNOLOGY VALUE FUND II LP | Reporting Owner | 248,144 | 2014-03-24 | S |
| BVF INC/IL | 10%+ Owner | 248,144 | 2014-03-24 | S |
| LAMPERT MARK N | 10%+ Owner | 248,144 | 2014-03-24 | S |
| BVF INVESTMENTS LLC | Reporting Owner | 248,144 | 2014-03-24 | S |
| Davis Todd C | Director · Officer | 199,513 | 2026-06-30 | J |
| FOEHR MATTHEW W | Reporting Owner | 162,187 | 2022-11-01 | D |
| Aryeh Jason | Director | 107,580 | 2026-06-05 | A |
| MAIER PAUL V | Officer | 105,267 | 2006-11-20 | M |
| MEGLASSON MARTIN | Officer | 102,250 | 2010-05-11 | P |
| KNOTT DAVID M | Director | 66,152 | 2015-08-17 | S |
| Korenberg Matthew E | Officer | 60,549 | 2024-09-23 | M |
| Espinoza Octavio | Officer | 59,337 | 2026-08-12 | M |
| CROUCH TAYLOR | Director | 45,000 | 2006-12-05 | M |
| DeSilva Nishan M | Officer | 43,220 | 2015-05-14 | M |
| KOZARICH JOHN W | Director | 42,622 | 2026-06-05 | A |
| Reardon Andrew | Officer | 36,854 | 2026-10-02 | M |
| Sabba Stephen L | Director | 35,774 | 2026-06-16 | M |
| Sharp John P | Officer | 34,333 | 2014-02-12 | M |
| Dziewanowska Zofia E | Officer | 33,977 | 2009-02-25 | S |
| Perry Jeffrey R | Director | 33,953 | 2008-05-29 | A |
| GROVES ERIC S | Officer | 32,603 | 2006-12-15 | M |
| LAMATTINA JOHN L | Director | 31,303 | 2026-06-10 | S |
| Patel Sunil | Reporting Owner | 28,820 | 2022-11-01 | D |
| CROSS ALEXANDER D | Director | 26,335 | 2006-03-01 | M |
| Berkman Charles S | Reporting Owner | 23,825 | 2022-11-01 | D |
| BROADDUS WARNER R | Officer | 20,313 | 2006-11-17 | M |
| Kazmi Syed | Officer | 18,230 | 2012-02-09 | A |
| PETTTIT WILLIAM A | Officer | 17,985 | 2006-12-15 | M |
| BLISSENBACH HENRY F | Director | 15,005 | 2007-04-02 | M |
| Burakoff Steven J | Director | 15,000 | 2009-05-29 | A |
| NEGRO-VILAR ANDRES | Officer | 12,858 | 2006-12-14 | M |
| ROCCA MICHAEL A | Director | 11,676 | 2006-01-04 | A |
| Haas Jason | Director | 11,119 | 2026-08-12 | M |
| PEACOCK BRUCE | Director | 10,000 | 2008-12-23 | — |
| GREETHAM ELIZABETH M | Director | 10,000 | 2008-05-29 | A |
| LIGAND PHARMACEUTICALS INC | 10%+ Owner | 10,000 | 2008-08-04 | A |
| Gray Nancy Ryan | Director | 8,930 | 2026-06-05 | A |
| PECK CARL C | Director | 8,378 | 2006-01-04 | A |
| Zimmermann Martine | Director | 3,782 | 2026-09-22 | F |
| Herman Melanie J | Officer | 3,454 | 2016-06-30 | J |
| Boyce Sarah | Reporting Owner | 2,892 | 2022-11-01 | D |
| Roberts Brigette | Director | 2,378 | 2006-01-04 | A |
| Cochran Jennifer R. | Reporting Owner | 1,161 | 2022-11-01 | D |
| Dembitz Terry A | Officer | 262 | 2007-03-01 | — |
Recent Filings
| Date | Owner | Activity | Shares | Price | Owned After |
|---|---|---|---|---|---|
| 2026-10-02 | Reardon Andrew | Option exercise (derivative) | 340 | $0.00 | 29,104 |
| 2026-10-02 | Reardon Andrew | Open-market sale | 17 | $307.74 | 31,854 |
| 2026-10-02 | Reardon Andrew | Open-market sale | 235 | $307.19 | 31,871 |
| 2026-10-02 | Reardon Andrew | Open-market sale | 404 | $306.18 | 32,106 |
| 2026-10-02 | Reardon Andrew | Open-market sale | 1,535 | $304.52 | 32,510 |
| 2026-10-02 | Reardon Andrew | Open-market sale | 1,976 | $303.54 | 34,045 |
| 2026-10-02 | Reardon Andrew | Open-market sale | 833 | $302.51 | 36,021 |
| 2026-10-02 | Reardon Andrew | Option exercise | 340 | $52.27 | 36,854 |
| 2026-09-22 | Zimmermann Martine | Tax withholding | 115 | $298.50 | 3,782 |
| 2026-09-10 | Zimmermann Martine | Open-market sale | 1,200 | $285.00 | 3,897 |
| 2026-09-03 | Reardon Andrew | Open-market sale | 400 | $288.98 | 36,514 |
| 2026-09-03 | Reardon Andrew | Open-market sale | 385 | $287.53 | 36,914 |
| 2026-09-03 | Reardon Andrew | Open-market sale | 2,115 | $286.36 | 37,299 |
| 2026-09-03 | Reardon Andrew | Open-market sale | 1,800 | $285.17 | 39,414 |
| 2026-09-03 | Reardon Andrew | Open-market sale | 300 | $283.99 | 41,214 |
| 2026-08-12 | Haas Jason | Option exercise (derivative) | 6,138 | $0.00 | 0 |
| 2026-08-12 | Haas Jason | Open-market sale | 7,138 | $292.81 | 3,981 |
| 2026-08-12 | Haas Jason | Option exercise | 6,138 | $51.56 | 11,119 |
| 2026-08-12 | Espinoza Octavio | Option exercise (derivative) | 16,179 | $0.00 | 0 |
| 2026-08-12 | Espinoza Octavio | Option exercise (derivative) | 2,869 | $0.00 | 0 |
| 2026-08-12 | Espinoza Octavio | Open-market sale | 31,641 | $292.06 | 27,696 |
| 2026-08-12 | Espinoza Octavio | Option exercise | 3,348 | $68.74 | 59,337 |
| 2026-08-12 | Espinoza Octavio | Option exercise | 7,171 | $57.22 | 55,989 |
| 2026-08-12 | Espinoza Octavio | Option exercise | 2,869 | $55.75 | 48,818 |
| 2026-08-12 | Espinoza Octavio | Option exercise | 2,074 | $70.04 | 45,949 |
| 2026-08-12 | Espinoza Octavio | Option exercise | 16,179 | $52.84 | 43,875 |
| 2026-08-03 | Reardon Andrew | Option exercise (derivative) | 5,000 | $0.00 | 29,444 |
| 2026-08-03 | Reardon Andrew | Open-market sale | 409 | $292.82 | 41,514 |
| 2026-08-03 | Reardon Andrew | Open-market sale | 991 | $291.71 | 41,923 |
| 2026-08-03 | Reardon Andrew | Open-market sale | 200 | $290.60 | 42,914 |
| 2026-08-03 | Reardon Andrew | Open-market sale | 503 | $289.80 | 43,114 |
| 2026-08-03 | Reardon Andrew | Open-market sale | 356 | $288.75 | 43,617 |
| 2026-08-03 | Reardon Andrew | Open-market sale | 1,214 | $287.77 | 43,973 |
| 2026-08-03 | Reardon Andrew | Open-market sale | 1,032 | $286.80 | 45,187 |
| 2026-08-03 | Reardon Andrew | Open-market sale | 157 | $285.74 | 46,219 |
| 2026-08-03 | Reardon Andrew | Open-market sale | 33 | $284.55 | 46,376 |
| 2026-08-03 | Reardon Andrew | Open-market sale | 105 | $284.14 | 46,409 |
| 2026-08-03 | Reardon Andrew | Option exercise | 5,000 | $52.27 | 46,514 |
| 2026-07-01 | Reardon Andrew | Option exercise (derivative) | 5,000 | $0.00 | 34,444 |
| 2026-07-01 | Reardon Andrew | Open-market sale | 600 | $317.15 | 41,514 |
Source: SEC EDGAR Form 4 filings. For informational purposes only — not investment advice.